Inherited thrombophilia and adverse pregnancy outcome: Has the time come for selective testing?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 6, 1999, Pages 513-515

  Nelson Piercy, Catherine ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; HEPARIN; LUPUS ANTICOAGULANT;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; FETUS OUTCOME; HEALTH CARE POLICY; HUMAN; HYPERHOMOCYSTEINEMIA; NOTE; PATHOGENESIS; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENT ABORTION; SCREENING; THROMBOPHILIA;

FEMALE; GENETIC SCREENING; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; THROMBOPHILIA;

EID: 0032987378     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08316.x     Document Type: Note

References (26)

1. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–1589.
2. Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253–257.
3. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obsret Gynecol 1992; 80: 614–620.
4. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131–136.
5. Bertault D, Mandelbrot L, Tchobroutsky C, Sultan Y. Unfavourable pregnancy outcome associated with congenital protein C deficiency. Br J Obstet Gynaecol 1991; 98: 934–935.
6. Dekker GA, De Vries JIP, Doelizsch PM et al. Underlying disorders associated with severe early-onset pre-eclampsia. Am J Obstet Gynecol 1995; 173: 1042–1048.
7. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913–916.
8. DeVries JIP, Dekker GA, Huijgens PC, Jakobs C, von Blomberg BME, Van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obster Gynaecol 1997; 104: 1248–1254.
9. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489–490.
10. Brenner B, Mandel H, Lanir N et al. Activated protein C resistance can he associated with recurrent fetal loss. Br J Huemafol 1997; 97: 551–554.
11. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Pre-eclampsia is associated with a reduced response to activated protein C. Am J Obsret Gynecol 1997; 176: 457–460.
12. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe pre-eclampsia. Am J Obsret Gynecol 1997; 175: 902–905.
13. Rotmensch S, Liherati M, Mittelmann M, Benrafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997; 177: 170–173.
14. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obsret Gynecol 1997; 177: 402–405.
15. Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V Leiden mutation-an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis. Ann Neurol 1997; 42: 372–375.
16. Balasch J, Reverter JC, Fabregues F et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 1094–1097.
17. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217–223.
18. Wouters MGAJ, Boers GHJ, Blom HJ et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fed1 Steril 1993; 60: 820–825.
19. Goddijn-Wessel TAW, Wouters MGAJ, van DerMolen EF et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obsret Gynecol Rep Biol 1996; 66: 23–29.
20. Nelen WLDM, Steegers EAP, Eskes TUB, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancer 1997; 350: 861.
21. Rajkovic A, Catalano PM, Malinow MR. Elevated homocysteine levels with pre-eclampsia. Obsret Gynecol 1997; 90: 168–171.
22. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9–13.
23. Krause I, Blank M, Gilhrut B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 1993; 29: 155–161.
24. Richards EM, Makris M, Preston FE. The successful use of protein C concentrate during pregnancy in a patient with Qpe 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol 1997; 98: 660–661.
25. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Huemost 1998; 79: 1166–1170.
26. Nelson-Piercy C. Hazards of heparin: bleeding, allergy, heparininduced thrombocytopenia, osteoporosis. In: Greer I, editor. Thromboembolic Disease in Obstetrics and Gynaecology. London: Bailliere's Clinical Obstetrics and Gynaecology, 1997: 489–509.